129 related articles for article (PubMed ID: 10846831)
1. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy.
Sekine R; Taketazu F; Kuroki M; Takagi S; Imawari M; Kanazawa Y; Kawakami M
Int J Hematol; 2000 Apr; 71(3):256-8. PubMed ID: 10846831
[TBL] [Abstract][Full Text] [Related]
2. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
3. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
5. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
[TBL] [Abstract][Full Text] [Related]
9. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.
Sugauchi F; Tanaka Y; Kusumoto S; Matsuura K; Sugiyama M; Kurbanov F; Ueda R; Mizokami M
J Med Virol; 2011 Mar; 83(3):412-8. PubMed ID: 21264861
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
[TBL] [Abstract][Full Text] [Related]
11. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
[TBL] [Abstract][Full Text] [Related]
12. Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.
el-Sayed MH; Shanab G; Karim AM; el-Tawil A; Black A; Dixon JS
Pediatr Hematol Oncol; 2004 Mar; 21(2):145-56. PubMed ID: 15160513
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
Lubel JS; Angus PW
J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
[TBL] [Abstract][Full Text] [Related]
14. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.
Stange MA; Tutarel O; Pischke S; Schneider A; Strassburg CP; Becker T; Barg-Hock H; Bastürk M; Wursthorn K; Cornberg M; Ott M; Greten TF; Manns MP; Wedemeyer H
Z Gastroenterol; 2010 Feb; 48(2):258-63. PubMed ID: 20127601
[TBL] [Abstract][Full Text] [Related]
15. [Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma].
van der Eijk AA; Doorduijn JK; Janssen HL; Schalm SW; Niesters HG; de Man RA
Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1140-4. PubMed ID: 12092307
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K
Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
[TBL] [Abstract][Full Text] [Related]
17. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
18. [A fatal case of a hepatitis B virus carrier with fulminant hepatic failure after cytotoxic chemotherapy for malignant lymphoma].
Kumagai K; Takagi T; Sakai C; Oguro M; Kawai S; Nakahori S; Yokosuka O; Ohtoh M
Rinsho Ketsueki; 1993 Dec; 34(12):1587-9. PubMed ID: 8295335
[TBL] [Abstract][Full Text] [Related]
19. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region.
Kitano K; Kobayashi H; Hanamura M; Furuta K; Ueno M; Rokuhara A; Tanaka E; Umemura T; Kiyosawa K
Eur J Haematol; 2006 Sep; 77(3):255-8. PubMed ID: 16923112
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
